Sarepta Setback: FDA Doubts About DMD Biomarker Crushes Early Approval Dreams
This article was originally published in The Pink Sheet Daily
FDA’s rejection of dystrophin as a biomarker in Duchenne muscular dystrophy and doubts about the six-minute walk test endpoint put Sarepta back at square one.
You may also be interested in...
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
“The spin-off will establish two separate companies, a fully integrated, pure play, eye health company built on the iconic Bausch Health brand and a long history of innovation, and an international diversified pharmaceutical company with leading physicians in gastroenterology, dermatology, aesthetics, neurology and an international pharma business,” says CEO Joseph Papa.
The company formerly known as Valeant, put together by a series of mergers, is ready to spin out the legacy Bausch + Lomb eyecare business that it used in its rebranding.